PLUGGING IN

Harris County connects students in need to free high-speed internet and devices

Harris County is making sure all kids stay connected during the pandemic. Photo courtesy of Pixlr

Schools around the nation are in a rush to return to normalcy despite the pandemic. So varied are the opinions on how to reopen that Harris County Judge Lina Hidalgo just released a "roadmap" for reopening.

One pressing issue is the massive digital divide between households that have internet access at home and those that do not — especially as school districts push for virtual learning. Roughly one-third of households with children ages 6 to 17 and an annual income below $30,000 a year do not have a high-speed internet connection at home, according to a 2020 Pew Research Study.

To that end, the Harris County Commissioners Court approved two programs aiming to end the digital divide in Harris County. The $32 million combined programs will provide more than 120,000 mobile hot spots (with unlimited data plans) and more than 250,000 devices (such as tablets and laptops) for students during the pandemic and for the remainder of the school year, according to a press release.

The programs use CARES Act Funds allocated by the Federal Government. A dollar-for-dollar match from the Texas Education Agency is also part of the funding. Nationwide carriers T-Mobile, AT&T, and Verizon are partnering with the program.

Once purchased, the devices and hot spots will become permanent property of the districts, which will then distribute to students within four and 12 weeks, according to the release.

"On one hand, I am thrilled we are offering help to families with the goal of flattening the education access curve," said Commissioner Garcia. "However, it pains me that it took a pandemic to close the gap between kids with reliable access to the internet at home and those that, in some cases are having to use mom or dad's smartphone to do their homework, if such a device is even available in the home. This is a great example of what we can accomplish when the state of Texas and local counties work together to help people in need."

------

This article originally ran on CultureMap.

Trending News

Building Houston

 
 

Tvardi Therapeutics Inc. has fresh funds to support its drug's advancement in clinical trials. Photo via Getty Images

A Houston-based clinical-stage biopharmaceutical company has raised millions in its latest round.

Tvardi Therapeutics Inc. closed its $74 million series B funding round led by new investors New York-based Slate Path Capital, Florida-based Palkon Capital, Denver-based ArrowMark Partners, and New York-based 683 Capital, with continued support and participation by existing investors, including Houston-based Sporos Bioventures.

"We are thrilled to move out of stealth mode and partner with this lineup of long-term institutional investors," says Imran Alibhai, CEO at Tvardi. "With this financing we are positioned to advance the clinical development of our small molecule inhibitors of STAT3 into mid-stage trials as well as grow our team."

Through Slate Path Capital's investment, Jamie McNab, partner at the firm, will join Tvardi's board of directors.

"Tvardi is the leader in the field of STAT3 biology and has compelling proof of concept clinical data," McNab says in the release. "I look forward to partnering with the management team to advance Tvardi's mission to develop a new class of breakthrough medicines for cancer, chronic inflammation, and fibrosis."

Tvardi's latest fundraise will go toward supporting the company's products in their mid-stage trials for cancer and fibrosis. According to the release, Tvardi's lead product, TTI-101, is being studied in a Phase 1 trial of patients with advanced solid tumors who have failed all lines of therapy. So far, the drug has been well-received and shown multiple durable radiographic objective responses in the cancer patients treated.

Dr. Keith Flaherty, who is a member of Tvardi's scientific advisory board and professor of medicine at Harvard Medical School, offered his support of the company.

"STAT3 is a compelling and validated target. Beyond its clinical activity, Tvardi's lead molecule, TTI-101, has demonstrated direct downregulation of STAT3 in patients," he says in the release. "As a physician, I am eager to see the potential of Tvardi's molecules in diseases of high unmet medical need where STAT3 is a key driver."

Trending News